Form 4 for ETON Eton Pharmaceuticals, Inc.

Accepted 2026-01-14 00:00:00 ET · period of report 2026-01-12 · accession 0001437749-26-001288 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-01-14	2026-01-14	ETON	Krempa David	Chief Business Off	F - Tax	$15.62	-1,942	630.2K	-0.3%	-$30.3K
DM	2026-01-14	2026-01-12	ETON	Krempa David	Chief Business Off	A - Grant	$0.00	+66.5K	696.7K	+11%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-01-14	F	D	1,942	$15.62	630,238	D	—	—	(F1) Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. (F2) The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
2	Derivative	Employee Stock Option (Right to Buy)	2026-01-12	A	A	40,655	$0.00	670,893	D	$15.47 · — to 2036-01-11	40,655 Common Stock	(F3) The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
3	Derivative	Restricted Stock Units	2026-01-12	A	A	25,856	$0.00	696,749	D	— · — to —	25,856 Common Stock	(F4) Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. (F5) The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.